CARsgen Therapeutics Holdings Limited Announces Inclusion in Southbound Stock Connect

CARsgen Therapeutics Holdings Limited (“CARsgen” or the “Company”, Stock Code: 2171), a leading biopharmaceutical company focused on innovative CAR-T cell therapies, has made an important announcement that could significantly impact its share value and investment profile.

Key Highlights

• Inclusion in Southbound Stock Connect: The shares of CARsgen, listed on The Stock Exchange of Hong Kong Limited, have been officially included in the list of eligible shares for Southbound Trading under both the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs. This inclusion becomes effective from March 9, 2026.
• Market Recognition: The inclusion reflects market confidence in CARsgen’s core CAR-T business, operational compliance, and share liquidity. It underscores the Company’s development potential and aligns with its long-term growth strategy.
• Access for Mainland Investors: Eligible investors from mainland China will have direct access to invest in CARsgen shares via the Stock Connect trading systems of the Shanghai and Shenzhen Stock Exchanges. This is expected to increase investor base and facilitate cross-border investment flows.
• Enhanced Liquidity and Market Attention: The Stock Connect inclusion is anticipated to significantly boost market attention and trading liquidity for CARsgen shares, potentially driving up share price and improving capital market visibility.

Implications for Shareholders

• Potential Share Price Impact: The greater accessibility for mainland investors may result in increased trading volumes, higher liquidity, and potentially upward pressure on share prices. This development is considered price sensitive and could affect the valuation of CARsgen shares.
• Alignment with Shareholder Interests: The move supports the fundamental interests of all shareholders, as it expands the pool of potential investors and aligns with CARsgen’s strategic focus on growth and innovation.
• Caution Advised: The Company specifically advises shareholders and potential investors to exercise caution when dealing in the shares, acknowledging that the inclusion may cause increased volatility or speculative trading.

Corporate Governance

The board of directors, led by Chairman Dr. Zonghai LI, includes a mix of executive, non-executive, and independent directors, ensuring robust oversight and governance as the Company enters this new phase of market engagement.

Conclusion

The inclusion of CARsgen Therapeutics Holdings Limited in the Southbound Stock Connect is a significant milestone, providing greater visibility, liquidity, and investment potential. This move is likely to attract new investors, increase market attention, and potentially drive share price appreciation. Investors should monitor the impact closely and consider the changing dynamics when making investment decisions.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Shareholders and potential investors should conduct their own due diligence and consult with professional advisors before making any investment decisions. The Company has advised caution when dealing in its shares following this announcement.

View CARSGEN-B Historical chart here